Strategic Forecast for the Biologic & Biosimilar RA Drugs Industry: Market Outlook 2025-2034

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

Biologic & Biosimilar RA Drugs Market Size Growth Forecast: What to Expect by 2025?
In recent times, the biologic & biosimilar ra drugs market has seen substantial growth. Rising from $13.99 billion in 2024, the market is projected to further increase to $14.71 billion in 2025, with a compound annual growth rate (CAGR) of 5.2%. Factors such as adoption rates in the market, results from clinical trials, changes in market share, long-term results for patients, and pricing strategies have contributed to its growth during the historic period.

How Will the Biologic & Biosimilar RA Drugs Market Size Evolve and Grow by 2029?
The market size of biologic and biosimilar ra drugs is projected to experience substantial expansion in the ensuing years, escalating to a worth of $19.51 billion by 2029 with a compound annual growth rate (CAGR) of 7.3%. This predicted increase during the forecast period can be traced back to factors such as the augmentation in biologic drug development, intensifying market competition, evolving healare policies, patient predilections, along with clinical research and development. Key trends expected during the forecast period encompass the surge in biosimilar market competition, the rise in personalized medicine and precision therapy, breakthroughs in drug delivery systems, an emphasis on safety and efficacy, and a patient-focused approach in healare.

View the full report here:
https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

What Drivers Are Propelling the Growth of Biologic & Biosimilar RA Drugs Market Forward?
The upward trend in the aged populace and escalating prevalence of rheumatoid arthritis in society lend impetus to the growth of biologics and biosimilars RA drugs market. The latter refers to those who have journeyed 60 years or more in life. Rheumatoid arthritis is essentially a disorder where an individual's immune system wrongfully attacks its own healthy cells with joints being the main brunt bearers. This discordance, unfortunately, tends to mount with advancing age due to the declining efficiency of the immune system. Compared to conventional medicines, biologics, and biosimilar RA drugs prove to be much more effective in treating rheumatoid arthritis. Reliable data from the World Health Organization (WHO), a UN-affiliated specialized health organization based in Switzerland, estimated the global count of individuals aged 60 or more to be around one billion in 2020. This number is anticipated to burgeon to 1.4 billion by 2030 and further surge to 2.1 billion by 2050. Additionally, projections by the Centers for Disease Control and Prevention, a US governmental public health body, predict arthritis affliction in adults in the USA to rise to 78.4 million by 2040. Concurrently, around 34.6 million people might face limitations in activities due to arthritis-related issues. Consequently, the upward geriatric population coupled with burgeoning RA incidences fuels the growth of the biologics and biosimilars RA drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp

Which Emerging Trends Are Transforming the Biologic & Biosimilar RA Drugs Market in 2025?
New advancements and breakthroughs are becoming a significant trend, particularly in the biologic & biosimilar RA drugs market. A key strategy for major companies in this sector is the development of biosimilar therapies such as Dual Concentration Biosimilar Options to provide cost-effective alternatives. In July 2023, US healare company Organon, in partnership with South Korea's Samsung Bioepis, introduced HADLIMA, a biosimilar to Humira (adalimumab), in the American market. HADLIMA, available in both high and low concentrations, is aimed to improve availability and cost-effectiveness for patients dealing with autoimmune diseases. The biosimilar is offered at a striking 85% lesser price than Humira, thereby improving patient accessibility. HADLIMA comes with an autoinjector certified by the Arthritis Foundation, along with a patient support program called HADLIMA For You, which offers educational resources and assistance with co-pay. HADLIMA, recommended for various medical conditions such as rheumatoid arthritis and Crohn's disease, is available in citrate-free high concentration (100 mg/mL) and citrate-inclusive low concentration (50 mg/mL) enabling uninterrupted patient care.

What Are the Key Segments in the Biologic & Biosimilar RA Drugs Market?
The biologic & biosimilar RA drugs market covered in this report is segmented -

1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources
2) By Mammalian: Chinese Hamster (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines
3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp

Who Are the Key Players Shaping the Biologic & Biosimilar RA Drugs Market's Competitive Landscape?
Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

What Geographic Markets Are Powering Growth in the Biologic & Biosimilar RA Drugs Market?
North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9255

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.